Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.

Diaz-Manera J, Kishnani PS, Kushlaf H, Ladha S, Mozaffar T, Straub V, Toscano A, van der Ploeg AT, Berger KI, Clemens PR, Chien YH, Day JW, Illarioshkin S, Roberts M, Attarian S, Borges JL, Bouhour F, Choi YC, Erdem-Ozdamar S, Goker-Alpan O, Kostera-Pruszczyk A, Haack KA, Hug C, Huynh-Ba O, Johnson J, Thibault N, Zhou T, Dimachkie MM, Schoser B, COMET Investigator Group

Open source

DOI: 10.1016/s1474-4422(21)00241-6
Published: 2021 Dec
Container: The Lancet. Neurology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1474-4422-21-00241-6,
  title = {Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.},
  author = {Diaz-Manera J and Kishnani PS and Kushlaf H and Ladha S and Mozaffar T and Straub V and Toscano A and van der Ploeg AT and Berger KI and Clemens PR and Chien YH and Day JW and Illarioshkin S and Roberts M and Attarian S and Borges JL and Bouhour F and Choi YC and Erdem-Ozdamar S and Goker-Alpan O and Kostera-Pruszczyk A and Haack KA and Hug C and Huynh-Ba O and Johnson J and Thibault N and Zhou T and Dimachkie MM and Schoser B and COMET Investigator Group},
  year = {2021},
  journal = {The Lancet. Neurology},
  doi = {10.1016/s1474-4422(21)00241-6},
  url = {https://doi.org/10.1016/s1474-4422(21)00241-6}
}

RIS

TY  - JOUR
TI  - Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
AU  - Diaz-Manera J
AU  - Kishnani PS
AU  - Kushlaf H
AU  - Ladha S
AU  - Mozaffar T
AU  - Straub V
AU  - Toscano A
AU  - van der Ploeg AT
AU  - Berger KI
AU  - Clemens PR
AU  - Chien YH
AU  - Day JW
AU  - Illarioshkin S
AU  - Roberts M
AU  - Attarian S
AU  - Borges JL
AU  - Bouhour F
AU  - Choi YC
AU  - Erdem-Ozdamar S
AU  - Goker-Alpan O
AU  - Kostera-Pruszczyk A
AU  - Haack KA
AU  - Hug C
AU  - Huynh-Ba O
AU  - Johnson J
AU  - Thibault N
AU  - Zhou T
AU  - Dimachkie MM
AU  - Schoser B
AU  - COMET Investigator Group
PY  - 2021
JO  - The Lancet. Neurology
DO  - 10.1016/s1474-4422(21)00241-6
UR  - https://doi.org/10.1016/s1474-4422(21)00241-6
ER  -

APA

J, D., PS, K., H, K., S, L., T, M., V, S., A, T., AT, V. D. P., KI, B., PR, C., YH, C., JW, D., S, I., M, R., S, A., JL, B., F, B., YC, C., S, E., O, G., A, K., KA, H., C, H., O, H., J, J., N, T., T, Z., MM, D., B, S., & Group, C. I. (2021). Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(21)00241-6

Source records

pubmed · retrieved 2026-09-26T07:02:50.798Z